SK Biopharmaceuticals Co., Ltd. (KRX:326030)
South Korea · Delayed Price · Currency is KRW 78,400
-600 (-0.76%)
At close: Aug 3, 2026
SK Biopharmaceuticals Market Cap
SK Biopharmaceuticals has a market cap or net worth of 6.19 trillion as of August 3, 2026. Its market cap has decreased by -15.78% in one year.
Market Cap
6.19T
Enterprise Value
5.93T
Revenue
790.25B
Ranking
n/a
PE Ratio
17.74
Stock Price
78,400.00
ChartMarket Cap Chart
Since July 2, 2020, SK Biopharmaceuticals's market cap has decreased from 9.95T to 6.19T, a decrease of -37.80%. That is a compound annual growth rate of -7.50%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 3, 2026 | 6.19T | -36.60% |
| Dec 30, 2025 | 9.76T | 12.15% |
| Dec 30, 2024 | 8.70T | 10.66% |
| Dec 28, 2023 | 7.86T | 39.25% |
| Dec 29, 2022 | 5.65T | -25.82% |
| Dec 30, 2021 | 7.61T | -42.49% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Jul 2, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| ALTEOGEN | 16.52T |
| Samsung Epis Holdings | 9.18T |
| HLB Co., Ltd. | 4.11T |
| ABL Bio | 3.98T |
| LigaChem Biosciences | 3.22T |
| Peptron | 2.98T |
| SK bioscience | 2.68T |
| Hugel | 2.51T |